Circulating levels of soluble fas ligand in cachexic patients with COPD are higher than those in non-cachexic patients with COPD

Internal Medicine

Volumn 44, Issue 11, 2005, Pages 1137-1143

  Takabatake, Noriaki ^a   Arao, Tsuyoshi ^a   Sata, Makoto ^a   Inoue, Sumito ^a   Abe, Shuichi ^a   Shibata, Yoko ^a   Kubota, Isao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cachexia; COPD; Fas Fas ligand system

Indexed keywords

FAS ANTIGEN; FAS LIGAND; BIOLOGICAL MARKER; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR;

ADIPOSE TISSUE; AGED; APOPTOSIS; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CACHEXIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPLETION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SKELETAL MUSCLE; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; HOSPITALIZATION; PATHOLOGY; PHYSIOLOGY; PROGNOSIS;

ADIPOSE TISSUE; AGED; APOPTOSIS; BIOLOGICAL MARKERS; BODY MASS INDEX; CACHEXIA; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTORS;

EID: 33644840228     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.1137     Document Type: Article

References (32)

1. Schols AM. Pulmonary cachexia. Int J Cardiol 85: 101-110, 2002.
2. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157: 1791-1797, 1998.
3. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160: 1856-1861, 1999.
4. Debigare R, Cote CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease: clinical relevance and mechanisms. Am J Respir Crit Care Med 164: 1712-1717, 2001.
5. Takabatake N, Nakamura H, Abe S, et al. Circulating leptin in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159: 1215-1219, 1999.
6. Agusti AG, Sauleda J, Miralles C, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166: 485-489, 2002.
7. Fischer-Posovszky P, Tornqvist H, Debatin KM, Wabitsch M. Inhibition of death-receptor mediated apoptosis in human adipocytes by the insulin-like growth factor I (IGF-I)/IGF-I receptor autocrine circuit. Endocrinology 145: 1849-1859, 2004.
8. Prins JB, Walker NI, Winterford CM, Cameron DP. Human adipocyte apoptosis occurs in malignancy. Biochem Biophys Res Commun 205: 625-630, 1994.
9. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 13: 2261-2267, 1999.
10. Takabatake N, Nakamura H, Inoue S, et al. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease. Respir Med 94: 1215-1220, 2000.
11. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152: S77-S121, 1995.
12. Yamaguchi S, Yamaoka M, Okuyama M, et al. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am J Cardiol 83: 1500-1503, 1999.
13. Bahr GM, Capron A, Dewulf J, et al. Elevated serum level of Fas ligand correlates with the asymptomatic stage of human immunodeficiency virus infection. Blood 90: 896-898, 1997.
14. Ichikura T, Majima T, Uchida T, Okura E, Ogawa T, Mochizuki H. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma. Oncol Rep 8: 311-314, 2001.
15. Japanese Society of Chest Disease. Standards of pulmonary function tests for Japanese. Jpn J Thorac Dis 31: appendix, 1993.
16. Kuwano K, Kawasaki M, Maeyama T, et al. Soluble form of fas and fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia. Chest 118: 451-458, 2000.
17. Takabatake N, Nakamura H, Minamihaba O, et al. A novel pathophysiologic phenomenon in cachexic patients with chronic obstructive pulmonary disease: the relationship between the circadian rhythm of circulating leptin and the very low-frequency component of heart rate variability. Am J Respir Crit Care Med 163: 1314-1319, 2001.
18. Nagata S. Apoptosis by death factor. Cell 88: 355-365, 1997.
19. Kang SM, Hoffmann A, Le D, Springer ML, Stock PG, Blau HM. Immune response and myoblasts that express Fas ligand. Science 278: 1322-1324, 1997.
20. Sata M, Walsh K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 4: 415-420, 1998.
21. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182: 1777-1783, 1995.
22. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 14: 1129-1135, 1995.
23. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 186: 2045-2050, 1997.
24. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762, 1994.
25. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154: 2706-2713, 1995.
26. Kuwano K, Maeyama T, Inoshima I, et al. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases. Respirology 7: 15-21, 2002.
27. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol 28: 555-562, 2003.
28. Yokohori N, Aoshiba K, Nagai A; Respiratory Failure Research Group in Japan. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest 125: 626-632, 2004.
29. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 163: 737-744. 2001.
30. Arao T, Takabatake N, Sata M, et al. In vivo evidence of endothelial injury in chronic obstructive pulmonary disease by lung scintigraphic assessment of (123)I-metaiodobenzylguanidine. J Nucl Med 44: 1747-1754, 2003.
31. Taieb J, Mathurin P, Poynard T, Gougerot-Pocidalo, MA, Chollet-Martin S. Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet 351: 1930-1931, 1998.
32. Takabatake N, Sata M, Abe S, et al. Impaired systemic cell-mediated immunity and increased susceptibility to acute respiratory tract infections in patients with COPD. Respir Med 99: 485-492, 2005.